Genetic Analysis Launches Microbiome Test in the US in Collaboration with Pangea Laboratory

Norwegian diagnostics company Genetic Analysis, in partnership with US-based Pangea Laboratory, is set to launch the microbiome-based GA-map MHI GutHealth test as a Research Use Only product on the American market. This announcement was made in a recent press release.

The test, to be conducted at Pangea’s laboratory in California, is the first of its kind to provide clinically relevant insights into antibiotic-induced microbiome disturbances.

Initially, the test will target patients suffering from recurrent Clostridioides difficile infection, a type of intestinal infection that affects approximately 500,000 Americans each year.

Under the terms of the collaboration, Genetic Analysis will supply reagent kits to Pangea and will generate revenue per test sold, with no volume commitments or additional investments required.